We will be comparing the differences between Emergent BioSolutions Inc. (NYSE:EBS) and Trillium Therapeutics Inc. (NASDAQ:TRIL) as far as profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent BioSolutions Inc.	782.40M	3.49	62.70M	1.14	50.80
Trillium Therapeutics Inc.	N/A	0.00	N/A	-2.55	0.00

Demonstrates Emergent BioSolutions Inc. and Trillium Therapeutics Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 shows us the return on assets, net margins and return on equity of both businesses.

	Net Margins	Return on Equity	Return on Assets
Emergent BioSolutions Inc.	8.01%	6.6%	4.5%
Trillium Therapeutics Inc.	0.00%	0%	0%

Analyst Ratings

Emergent BioSolutions Inc. and Trillium Therapeutics Inc. Ratings and Recommendations are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Emergent BioSolutions Inc.	0	2	3	2.60
Trillium Therapeutics Inc.	0	1	1	2.50

The upside potential is 32.53% for Emergent BioSolutions Inc. with average price target of $70.6. On the other hand, Trillium Therapeutics Inc.’s potential upside is 275.88% and its average price target is $2.5. The information presented earlier suggests that Trillium Therapeutics Inc. looks more robust than Emergent BioSolutions Inc. as far as analyst belief.

Insider & Institutional Ownership

Roughly 85% of Emergent BioSolutions Inc. shares are held by institutional investors while 39.41% of Trillium Therapeutics Inc. are owned by institutional investors. Insiders held roughly 3.4% of Emergent BioSolutions Inc.’s shares. On the other hand, insiders held about 0.37% of Trillium Therapeutics Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Emergent BioSolutions Inc.	-5.49%	-7.58%	-20.29%	-7.79%	17.08%	-2.73%
Trillium Therapeutics Inc.	-5.61%	-61.62%	-75.2%	-88.07%	-90.46%	-59.53%

For the past year Emergent BioSolutions Inc.’s stock price has smaller decline than Trillium Therapeutics Inc.

Summary

Emergent BioSolutions Inc. beats on 11 of the 12 factors Trillium Therapeutics Inc.

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The companyÂ’s marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. Its investigational stage product candidates include NuThrax, a next generation anthrax vaccine; UV-4B for dengue and influenza infections; GC-072 for Burkholderia pseudomallei; FLU-IG (NP025), a human polyclonal antibody therapeutic being developed to treat seasonal influenza; ZIKA-IG (NP024), a human polyclonal antibody therapeutic being developed as a prophylaxis for Zika infections; and FILOV (NP026), an equine polyclonal antibody therapeutic being developed to treat Ebola infections. In addition, the company provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.